protionamide 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
2314 14222-60-7

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • prothionamide
  • 2-Propylisonicotinylthioamide
  • 2-Propylthioisonicotinamide
  • protionamid
  • protionamide
Antitubercular agent similar in action and side effects to ETHIONAMIDE. It is used mostly in combination with other agents.
  • Molecular weight: 180.27
  • Formula: C9H12N2S
  • CLOGP: 2.26
  • LIPINSKI: 0
  • HAC: 2
  • HDO: 1
  • TPSA: 38.91
  • ALOGS: -2.79
  • ROTB: 3

Drug dosage:

DoseUnitRoute
0.75 g O

ADMET properties:

PropertyValueReference
BA (Bioavailability) 99 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

None

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hepatotoxicity 83.17 44.28 21 265 27205 50577633
Electrocardiogram QT prolonged 74.13 44.28 22 264 51864 50552974
Drug resistance 44.96 44.28 12 274 18977 50585861

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hepatotoxicity 232.28 55.86 57 565 17810 29556095
Electrocardiogram QT prolonged 100.76 55.86 35 587 36102 29537803

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hepatotoxicity 302.78 44.62 78 923 39884 64457847
Electrocardiogram QT prolonged 160.45 44.62 56 945 79392 64418339

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC J04AD01 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIMYCOBACTERIALS
DRUGS FOR TREATMENT OF TUBERCULOSIS
Thiocarbamide derivatives
MeSH PA D000900 Anti-Bacterial Agents
MeSH PA D000890 Anti-Infective Agents
MeSH PA D000995 Antitubercular Agents

Drug Use | Suggest Off label Use Form| |View source of the data|

None




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 11.43 acidic
pKa2 5.65 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Polyphenol oxidase 2 Enzyme IC50 5.35 CHEMBL

External reference:

IDSource
N0000167317 NUI
D01195 KEGG_DRUG
C0033705 UMLSCUI
CHEBI:32066 CHEBI
CHEMBL1378024 ChEMBL_ID
DB12667 DRUGBANK_ID
2031 INN_ID
76YOO33643 UNII
666418 PUBCHEM_CID
8871 RXNORM
006706 NDDF
703589003 SNOMEDCT_US
714517006 SNOMEDCT_US
D011515 MESH_DESCRIPTOR_UI

Pharmaceutical products:

None